Skip to main content
    A

    Anixa Biosciences Inc (ANIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.55
    -0.07 (-2.67%)

    Market Cap: $91.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anixa Biosciences Inc (ANIX) Financials: Revenue, Profit and Cash Flow

    Updated Sep 9, 2026. Financial statements from company filings, amounts in US dollars.

    Anixa Biosciences reported revenue of $0 for the fiscal year ended Oct 31, 2025. That year, net income was -$11.03M, operating cash flow was -$7.17M and free cash flow was -$7.17M. The quarter ended Jul 31, 2026 had revenue of $0 and net income of -$2.63M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Oct 2025, with an operating loss of $11.70M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Oct 2025$0N/AN/AN/AN/A
    Oct 2024$0-100.0%N/AN/AN/A
    Oct 2023$210.00KN/A100.0%-5243.3%-4728.6%
    Oct 2022$0-100.0%N/AN/AN/A
    Oct 2021$512.00KN/A24.8%-2565.6%-2528.6%
    Oct 2020$0-100.0%N/AN/AN/A
    Oct 2019$250.00K-77.5%100.0%-4756.0%-4727.5%
    Oct 2018$1.11M+206.9%100.0%-1284.4%-1280.3%
    Oct 2017$362.50K+20.8%100.0%-1676.0%-1381.8%
    Oct 2016$300.00KN/A100.0%-1503.0%-1672.1%
    Annual, fiscal years ended Oct 2016 to Oct 2025

    Income Statement

    In the fiscal year ended Oct 2025, the net loss narrowed from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020Oct 2019Oct 2018Oct 2017Oct 2016
    Revenue$0$0$210.00K$0$512.00K$0$250.00K$1.11M$362.50K$300.00K
    Cost of revenue$0$0$0$0$385.00K$0$0$0$0$0
    Gross profit$0$0$210.00K$0$127.00K$0$250.00K$1.11M$362.50K$300.00K
    Research and development$5.07M$6.40M$4.77M$6.70M$6.19M$4.38M$5.47M$6.81M$1.60M$1.56M
    Operating income-$11.70M-$13.83M-$11.01M-$13.88M-$13.14M-$9.98M-$11.89M-$14.29M-$6.08M-$4.51M
    Net income-$11.03M-$12.70M-$9.93M-$13.77M-$12.95M-$20.11M-$11.82M-$14.24M-$5.01M-$5.02M
    EBITDAN/A-$13.79M-$10.96M-$13.83M-$13.08M-$9.89M-$11.42M-$13.95M-$5.71M-$4.15M
    Fiscal years ended Oct 2016 to Oct 2025

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$156.00K
    Gross profit$0$0$0-$9.00K$0$0$0$0$0$0$0$144.00K
    Operating income-$2.74M-$2.65M-$2.72M-$2.88M-$2.44M-$3.00M-$3.39M-$3.16M-$3.59M-$3.47M-$3.61M-$3.05M
    Net income-$2.63M-$2.54M-$2.58M-$2.72M-$2.28M-$2.81M-$3.21M-$2.91M-$3.31M-$3.18M-$3.29M-$2.72M
    Last 12 quarters

    Balance Sheet

    As of Oct 2025, cash and equivalents exceeded short-term debt of $41.00K by $1.20M.

    Annual

    Line itemOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020Oct 2019Oct 2018Oct 2017Oct 2016
    Total assets$16.08M$21.59M$25.52M$30.41M$36.26M$9.45M$6.29M$6.45M$8.81M$5.63M
    Current assets$15.89M$21.36M$25.36M$30.20M$36.00M$9.37M$6.09M$5.54M$7.01M$3.40M
    Cash and equivalents$1.24M$1.27M$915.00K$12.36M$29.13M$6.42M$3.49M$3.06M$3.34M$2.49M
    Total liabilities$2.13M$2.70M$2.15M$2.21M$1.49M$1.19M$1.48M$1.27M$889.49K$4.64M
    Short-term debt$41.00K$29.00K$52.00K$46.00K$39.00K$55.20KN/AN/AN/AN/A
    Shareholder equity$15.16M$20.00M$24.34M$29.05M$35.44M$8.76M$5.24M$5.43M$7.92M$987.48K
    Fiscal years ended Oct 2016 to Oct 2025

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Total assets$15.07M$14.87M$15.23M$16.08M$17.65M$16.98M$18.91M$21.59M$22.91M$24.36M$25.37M$25.52M
    Total liabilities$1.87M$1.64M$1.39M$2.13M$2.24M$2.07M$2.19M$2.70M$2.22M$1.77M$1.77M$2.15M
    Cash and equivalents$1.40M$1.48M$1.55M$1.24M$1.50M$1.91M$1.05M$1.27M$1.23M$995.00K$998.00K$915.00K
    Shareholder equity$14.47M$14.47M$15.08M$15.16M$16.59M$16.07M$17.85M$20.00M$21.77M$23.62M$24.61M$24.34M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Oct 2025.

    Annual

    Line itemOct 2025Oct 2024Oct 2023Oct 2022Oct 2021Oct 2020Oct 2019Oct 2018Oct 2017Oct 2016
    Operating cash flow-$7.17M-$7.33M-$6.21M-$6.49M-$4.94M-$6.18M-$4.74M-$4.27M-$3.80M-$3.38M
    Capital expenditures$0$0$0$0$0$15.79K$175.46K$38.40K$30.19K$146.52K
    Free cash flow-$7.17M-$7.33M-$6.21M-$6.49M-$4.94M-$6.19M-$4.92M-$4.31M-$3.83M-$3.53M
    Investing cash flow$4.87M$4.28M-$5.60M-$10.73M-$3.92M-$305.79K-$525.46K$1.46M-$2.74M$1.50M
    Financing cash flow$2.28M$3.42M$366.00K$452.00K$31.57M$9.41M$5.70M$2.53M$7.38M-$2.68K
    Fiscal years ended Oct 2016 to Oct 2025

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$1.77M-$1.74M-$2.61M-$1.25M-$1.51M-$1.50M-$2.90M-$927.00K-$2.64M-$1.46M-$2.31M-$1.97M
    Free cash flowN/A-$1.74M-$2.61M-$1.25M-$1.51M-$1.50M-$2.90M-$927.00K-$2.64M-$1.46M-$2.31M-$1.97M
    Last 12 quarters

    Frequently Asked Questions About ANIX

    What is Anixa Biosciences' annual revenue?

    Anixa Biosciences reported revenue of $0 for the fiscal year ended Oct 31, 2025.

    Is Anixa Biosciences profitable?

    No. Anixa Biosciences reported net income of -$11.03M for the fiscal year ended Oct 31, 2025.

    How much free cash flow does ANIX generate?

    For the fiscal year ended Oct 31, 2025, operating cash flow of -$7.17M minus capital expenditures of $0 produced free cash flow of -$7.17M.

    How much debt does Anixa Biosciences have?

    The balance sheet dated Oct 31, 2025 reported short-term debt of $41.00K and cash and equivalents of $1.24M.